Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors

Summary

This phase II open-label study will be performed to evaluate the response rate of brain metastases from lung and breast tumors under treatment with WBRT and lapatinib.

Timeline

Start

2010-10

Primary completion

2014-08

Completion

2014-12

Drugs

Indications